Pomalidomide - ≥99%, high purity , CRL4(CRBN) E3 ubiquitin ligase inhibitor, CAS No.19171-19-8, CRL4(CRBN) E3 ubiquitin ligase inhibitor

Item Number

P125813

• Synonyms: Pomalidomide (CC-4047) | POMALIDOMIDE [EMA EPAR] | POMALIDOMIDE [WHO-DD] | SCHEMBL369172 | BCP02890 | DTXCID801323473 | Pomalyst | IMID-3 | 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione | LACTONE | SR-01000941573 | AC-26970 | MLS006011261 | AKOS0
• Specifications & Purity: Moligand™, ≥99%
• Biochemical and Physiological Mechanisms: Pomalidomide is an effective fetal hemoglobin (HbF) inducer that downregulates the key γ-globin repressors, SRY-box transcription factor 6 (SOX6), and BAF chromatin remodeling complex subunit (BCL11A).Pomalidomide is a second generation immunomodulato
• Storage Temp: Store at 2-8°C
• Shipped In: Wet ice
• Grade: Moligand™
• Action Type: INHIBITOR
• Mechanism of action: CRL4(CRBN) E3 ubiquitin ligase inhibitor
• Note: Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Product Description

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM.
Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog. An inhibitor of LPS-induced TNFαrelease.

Application：

Pomalidomide has been used:to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptides；for apoptosis studies and intracellular calcium analysis；as a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells.